 | • レポートコード：QYR9ST04154 • 出版社/出版日：QYResearch / 2019年9月2日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療・製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| ※当調査レポートでは、糖尿病性腎症の世界市場について調査・分析し、糖尿病性腎症の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（ACE阻害剤、ARB、利尿薬、カルシウムチャネル遮断薬（CCB）、レニン阻害剤、結合組織成長因子（CTGF）阻害剤、抗酸化炎症調節剤（AIM）、単球化学誘引タンパク質（MCP）阻害剤、エンドセリンA受容体（ETAR）アンタゴニスト Gタンパク質共役受容体（GPCR））、用途別（病院、がん研究所、診断研究所）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界の糖尿病性腎症市場動向 ・主要企業別マーケットシェア ・糖尿病性腎症の種類別市場規模2014-2019 （ACE阻害剤、ARB、利尿薬、カルシウムチャネル遮断薬（CCB）、レニン阻害剤、結合組織成長因子（CTGF）阻害剤、抗酸化炎症調節剤（AIM）、単球化学誘引タンパク質（MCP）阻害剤、エンドセリンA受容体（ETAR）アンタゴニスト Gタンパク質共役受容体（GPCR）） ・糖尿病性腎症の用途別市場規模2014-2019 （病院、がん研究所、診断研究所） ・糖尿病性腎症の北米市場：主要企業・種類別/用途別市場規模 ・糖尿病性腎症のヨーロッパ市場：主要企業・種類別/用途別市場規模 ・糖尿病性腎症の中国市場：主要企業・種類別/用途別市場規模 ・糖尿病性腎症の日本国内市場：主要企業・種類別/用途別市場規模 ・糖尿病性腎症の東南アジア市場：主要企業・種類別/用途別市場規模 ・糖尿病性腎症のインド市場：主要企業・種類別/用途別市場規模 ・糖尿病性腎症の中南米市場：主要企業・種類別/用途別市場規模 ・主要企業のプロフィール （Novartis、Merck、Pfizer、Abbott Laboratories、Sanofi、Eli Lilly、AbbVie、Reata Pharmaceuticals、Bayer、Mitsubishi Tanabe Pharma） ・糖尿病性腎症の市場規模予測2019-2025 （種類別、用途別、地域別市場予測） ・アナリストの観点・結論 ... |
Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications in terms of mortality and morbidity for patients with diabetes. Diabetic nephropathy is mainly characterized by macroalbuminuria. The presence of over 300 milligrams of albumin in the urine in 1 day is known as macroalbuminuria. Globally, the diabetic nephropathy market is witnessing significant growth due to rise in the incidence of diabetes and obesity in different regions of the world. In addition, increasing R&D investments in drug discovery and development by various companies, such as Sanofi, Eli Lilly and Mitsubishi Tanabe Pharma is also driving the growth of the market.North America has the largest market for the global diabetic nephropathy market. However, In terms of growth, Asia is the fastest growing region. Disease Modifying Therapies (DMT) is the largest and fastest growing mode of treatment, whereas ACE inhibitors, is the largest and fastest growing DMT of diabetic nephropathy.
Growing prevalence of diabetes and obesity, increasing R&D investments in drug discovery and development, and rising awareness about diabetes and kidney-related disorders are some of the major drivers of the diabetic nephropathy market. On the other hand, stringent regulatory requirements and longer approval time for drugs as well as a lack of comprehensive therapeutic management for diabetic nephropathy are major concerns for the market. Increasing usage of combination therapy is gaining popularity in diabetic nephropathy market is the recent market trends that have been observed in diabetic nephropathy market.
In 2018, the global Diabetic Nephropathy market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Diabetic Nephropathy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Diabetic Nephropathy development in United States, Europe and China.
The key players covered in this study
Novartis
Merck
Pfizer
Abbott Laboratories
Sanofi
Eli Lilly
AbbVie
Reata Pharmaceuticals
Bayer
Mitsubishi Tanabe Pharma
Market segment by Type, the product can be split into
ACE Inhibitors
ARBs
Diuretics
Calcium Channel Blockers(CCBs)
Renin Inhibitors
Connective Tissue Growth Factor (CTGF) Inhibitors
Antioxidant Inflammation Modulators(AIMs)
Monocyte Chemoattractant Protein (MCP)Inhibitors
Endothelin-A Receptor(ETAR)Antagonist
G Protein-Coupled Receptors (GPCRs)
Market segment by Application, split into
Hospitals
Cancer Research Institutes
Diagnostic Labs
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Diabetic Nephropathy status, future forecast, growth opportunity, key market and key players.
To present the Diabetic Nephropathy development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Diabetic Nephropathy are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Diabetic Nephropathy Market Size Growth Rate by Type (2014-2025)
1.4.2 ACE Inhibitors
1.4.3 ARBs
1.4.4 Diuretics
1.4.5 Calcium Channel Blockers(CCBs)
1.4.6 Renin Inhibitors
1.4.7 Connective Tissue Growth Factor (CTGF) Inhibitors
1.4.8 Antioxidant Inflammation Modulators(AIMs)
1.4.9 Monocyte Chemoattractant Protein (MCP)Inhibitors
1.4.10 Endothelin-A Receptor(ETAR)Antagonist
1.4.11 G Protein-Coupled Receptors (GPCRs)
1.5 Market by Application
1.5.1 Global Diabetic Nephropathy Market Share by Application (2014-2025)
1.5.2 Hospitals
1.5.3 Cancer Research Institutes
1.5.4 Diagnostic Labs
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Diabetic Nephropathy Market Size
2.2 Diabetic Nephropathy Growth Trends by Regions
2.2.1 Diabetic Nephropathy Market Size by Regions (2014-2025)
2.2.2 Diabetic Nephropathy Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities
3 Market Share by Key Players
3.1 Diabetic Nephropathy Market Size by Manufacturers
3.1.1 Global Diabetic Nephropathy Revenue by Manufacturers (2014-2019)
3.1.2 Global Diabetic Nephropathy Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Diabetic Nephropathy Market Concentration Ratio (CR5 and HHI)
3.2 Diabetic Nephropathy Key Players Head office and Area Served
3.3 Key Players Diabetic Nephropathy Product/Solution/Service
3.4 Date of Enter into Diabetic Nephropathy Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
4.1 Global Diabetic Nephropathy Market Size by Type (2014-2019)
4.2 Global Diabetic Nephropathy Market Size by Application (2014-2019)
5 United States
5.1 United States Diabetic Nephropathy Market Size (2014-2019)
5.2 Diabetic Nephropathy Key Players in United States
5.3 United States Diabetic Nephropathy Market Size by Type
5.4 United States Diabetic Nephropathy Market Size by Application
6 Europe
6.1 Europe Diabetic Nephropathy Market Size (2014-2019)
6.2 Diabetic Nephropathy Key Players in Europe
6.3 Europe Diabetic Nephropathy Market Size by Type
6.4 Europe Diabetic Nephropathy Market Size by Application
7 China
7.1 China Diabetic Nephropathy Market Size (2014-2019)
7.2 Diabetic Nephropathy Key Players in China
7.3 China Diabetic Nephropathy Market Size by Type
7.4 China Diabetic Nephropathy Market Size by Application
8 Japan
8.1 Japan Diabetic Nephropathy Market Size (2014-2019)
8.2 Diabetic Nephropathy Key Players in Japan
8.3 Japan Diabetic Nephropathy Market Size by Type
8.4 Japan Diabetic Nephropathy Market Size by Application
9 Southeast Asia
9.1 Southeast Asia Diabetic Nephropathy Market Size (2014-2019)
9.2 Diabetic Nephropathy Key Players in Southeast Asia
9.3 Southeast Asia Diabetic Nephropathy Market Size by Type
9.4 Southeast Asia Diabetic Nephropathy Market Size by Application
10 India
10.1 India Diabetic Nephropathy Market Size (2014-2019)
10.2 Diabetic Nephropathy Key Players in India
10.3 India Diabetic Nephropathy Market Size by Type
10.4 India Diabetic Nephropathy Market Size by Application
11 Central & South America
11.1 Central & South America Diabetic Nephropathy Market Size (2014-2019)
11.2 Diabetic Nephropathy Key Players in Central & South America
11.3 Central & South America Diabetic Nephropathy Market Size by Type
11.4 Central & South America Diabetic Nephropathy Market Size by Application
12 International Players Profiles
12.1 Novartis
12.1.1 Novartis Company Details
12.1.2 Company Description and Business Overview
12.1.3 Diabetic Nephropathy Introduction
12.1.4 Novartis Revenue in Diabetic Nephropathy Business (2014-2019)
12.1.5 Novartis Recent Development
12.2 Merck
12.2.1 Merck Company Details
12.2.2 Company Description and Business Overview
12.2.3 Diabetic Nephropathy Introduction
12.2.4 Merck Revenue in Diabetic Nephropathy Business (2014-2019)
12.2.5 Merck Recent Development
12.3 Pfizer
12.3.1 Pfizer Company Details
12.3.2 Company Description and Business Overview
12.3.3 Diabetic Nephropathy Introduction
12.3.4 Pfizer Revenue in Diabetic Nephropathy Business (2014-2019)
12.3.5 Pfizer Recent Development
12.4 Abbott Laboratories
12.4.1 Abbott Laboratories Company Details
12.4.2 Company Description and Business Overview
12.4.3 Diabetic Nephropathy Introduction
12.4.4 Abbott Laboratories Revenue in Diabetic Nephropathy Business (2014-2019)
12.4.5 Abbott Laboratories Recent Development
12.5 Sanofi
12.5.1 Sanofi Company Details
12.5.2 Company Description and Business Overview
12.5.3 Diabetic Nephropathy Introduction
12.5.4 Sanofi Revenue in Diabetic Nephropathy Business (2014-2019)
12.5.5 Sanofi Recent Development
12.6 Eli Lilly
12.6.1 Eli Lilly Company Details
12.6.2 Company Description and Business Overview
12.6.3 Diabetic Nephropathy Introduction
12.6.4 Eli Lilly Revenue in Diabetic Nephropathy Business (2014-2019)
12.6.5 Eli Lilly Recent Development
12.7 AbbVie
12.7.1 AbbVie Company Details
12.7.2 Company Description and Business Overview
12.7.3 Diabetic Nephropathy Introduction
12.7.4 AbbVie Revenue in Diabetic Nephropathy Business (2014-2019)
12.7.5 AbbVie Recent Development
12.8 Reata Pharmaceuticals
12.8.1 Reata Pharmaceuticals Company Details
12.8.2 Company Description and Business Overview
12.8.3 Diabetic Nephropathy Introduction
12.8.4 Reata Pharmaceuticals Revenue in Diabetic Nephropathy Business (2014-2019)
12.8.5 Reata Pharmaceuticals Recent Development
12.9 Bayer
12.9.1 Bayer Company Details
12.9.2 Company Description and Business Overview
12.9.3 Diabetic Nephropathy Introduction
12.9.4 Bayer Revenue in Diabetic Nephropathy Business (2014-2019)
12.9.5 Bayer Recent Development
12.10 Mitsubishi Tanabe Pharma
12.10.1 Mitsubishi Tanabe Pharma Company Details
12.10.2 Company Description and Business Overview
12.10.3 Diabetic Nephropathy Introduction
12.10.4 Mitsubishi Tanabe Pharma Revenue in Diabetic Nephropathy Business (2014-2019)
12.10.5 Mitsubishi Tanabe Pharma Recent Development
13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details
Table Diabetic Nephropathy Key Market Segments
Table Key Players Diabetic Nephropathy Covered
Table Global Diabetic Nephropathy Market Size Growth Rate by Type 2014-2025 (Million US$)
Figure Global Diabetic Nephropathy Market Size Market Share by Type 2014-2025
Figure ACE Inhibitors Figures
Table Key Players of ACE Inhibitors
Figure ARBs Figures
Table Key Players of ARBs
Figure Diuretics Figures
Table Key Players of Diuretics
Figure Calcium Channel Blockers(CCBs) Figures
Table Key Players of Calcium Channel Blockers(CCBs)
Figure Renin Inhibitors Figures
Table Key Players of Renin Inhibitors
Figure Connective Tissue Growth Factor (CTGF) Inhibitors Figures
Table Key Players of Connective Tissue Growth Factor (CTGF) Inhibitors
Figure Antioxidant Inflammation Modulators(AIMs) Figures
Table Key Players of Antioxidant Inflammation Modulators(AIMs)
Figure Monocyte Chemoattractant Protein (MCP)Inhibitors Figures
Table Key Players of Monocyte Chemoattractant Protein (MCP)Inhibitors
Figure Endothelin-A Receptor(ETAR)Antagonist Figures
Table Key Players of Endothelin-A Receptor(ETAR)Antagonist
Figure G Protein-Coupled Receptors (GPCRs) Figures
Table Key Players of G Protein-Coupled Receptors (GPCRs)
Table Global Diabetic Nephropathy Market Size Growth by Application 2014-2025 (Million US$)
Figure Hospitals Case Studies
Figure Cancer Research Institutes Case Studies
Figure Diagnostic Labs Case Studies
Figure Diabetic Nephropathy Report Years Considered
Table Global Diabetic Nephropathy Market Size 2014-2025 (Million US$)
Figure Global Diabetic Nephropathy Market Size and Growth Rate 2014-2025 (Million US$)
Table Global Diabetic Nephropathy Market Size by Regions 2014-2025 (Million US$)
Table Global Diabetic Nephropathy Market Size by Regions 2014-2019 (Million US$)
Table Global Diabetic Nephropathy Market Share by Regions 2014-2019
Figure Global Diabetic Nephropathy Market Share by Regions 2014-2019
Figure Global Diabetic Nephropathy Market Share by Regions 2019
Table Market Top Trends
Table Global Diabetic Nephropathy Revenue by Manufacturers (2014-2019) (Million US$)
Table Global Diabetic Nephropathy Market Share by Manufacturers (2014-2019)
Figure Global Diabetic Nephropathy Market Share by Manufacturers in 2018
Table Global Diabetic Nephropathy Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Key Players Head office and Area Served
Table Key Players Diabetic Nephropathy Product/Solution/Service
Table Date of Enter into Diabetic Nephropathy Market
Table Mergers & Acquisitions, Expansion Plans
Table Global Diabetic Nephropathy Market Size by Type (2014-2019) (Million US$)
Table Global Diabetic Nephropathy Market Size Share by Type (2014-2019)
Figure Global Diabetic Nephropathy Market Size Market Share by Type (2014-2019)
Table Global Diabetic Nephropathy Market Size by Application (2014-2019) (Million US$)
Table Global Diabetic Nephropathy Market Size Share by Application (2014-2019)
Figure Global Diabetic Nephropathy Market Size Market Share by Application (2014-2019)
Figure Global Diabetic Nephropathy Revenue Market Share by Application in 2018
Figure United States Diabetic Nephropathy Market Size 2014-2019 (Million US$)
Table United States Key Players Diabetic Nephropathy Revenue (2018-2019) (Million US$)
Table United States Key Players Diabetic Nephropathy Market Share (2018-2019)
Table United States Diabetic Nephropathy Market Size by Type (2014-2019) (Million US$)
Table United States Diabetic Nephropathy Market Share by Type (2014-2019)
Table United States Diabetic Nephropathy Market Size by Application (2014-2019) (Million US$)
Table United States Diabetic Nephropathy Market Share by Application (2014-2019)
Figure Europe Diabetic Nephropathy Market Size 2014-2019 (Million US$)
Table Europe Key Players Diabetic Nephropathy Revenue (2018-2019) (Million US$)
Table Europe Key Players Diabetic Nephropathy Market Share (2018-2019)
Table Europe Diabetic Nephropathy Market Size by Type (2014-2019) (Million US$)
Table Europe Diabetic Nephropathy Market Share by Type (2014-2019)
Table Europe Diabetic Nephropathy Market Size by Application (2014-2019) (Million US$)
Table Europe Diabetic Nephropathy Market Share by Application (2014-2019)
Figure China Diabetic Nephropathy Market Size 2014-2019 (Million US$)
Table China Key Players Diabetic Nephropathy Revenue (2018-2019) (Million US$)
Table China Key Players Diabetic Nephropathy Market Share (2018-2019)
Table China Diabetic Nephropathy Market Size by Type (2014-20189) (Million US$)
Table China Diabetic Nephropathy Market Share by Type (2014-2019)
Table China Diabetic Nephropathy Market Size by Application (2014-2019) (Million US$)
Table China Diabetic Nephropathy Market Share by Application (2014-2019)
Figure Japan Diabetic Nephropathy Market Size 2014-2019 (Million US$)
Table Japan Key Players Diabetic Nephropathy Revenue (2018-2019) (Million US$)
Table Japan Key Players Diabetic Nephropathy Market Share (2018-2019)
Table Japan Diabetic Nephropathy Market Size by Type (2014-2019) (Million US$)
Table Japan Diabetic Nephropathy Market Share by Type (2014-2019)
Table Japan Diabetic Nephropathy Market Size by Application (2014-2019) (Million US$)
Table Japan Diabetic Nephropathy Market Share by Application (2014-2019)
Figure Southeast Asia Diabetic Nephropathy Market Size 2014-2019 (Million US$)
Table Southeast Asia Key Players Diabetic Nephropathy Revenue (2018-2019) (Million US$)
Table Southeast Asia Key Players Diabetic Nephropathy Market Share (2018-2019)
Table Southeast Asia Diabetic Nephropathy Market Size by Type (2014-2019) (Million US$)
Table Southeast Asia Diabetic Nephropathy Market Share by Type (2014-2019)
Table Southeast Asia Diabetic Nephropathy Market Size by Application (2014-2019) (Million US$)
Table Southeast Asia Diabetic Nephropathy Market Share by Application (2014-2019)
Figure India Diabetic Nephropathy Market Size 2014-2019 (Million US$)
Table India Key Players Diabetic Nephropathy Revenue (2018-2019) (Million US$)
Table India Key Players Diabetic Nephropathy Market Share (2018-2019)
Table India Diabetic Nephropathy Market Size by Type (2014-2019) (Million US$)
Table India Diabetic Nephropathy Market Share by Type (2014-2019)
Table India Diabetic Nephropathy Market Size by Application (2014-2019) (Million US$)
Table India Diabetic Nephropathy Market Share by Application (2014-2019)
Figure Central & South America Diabetic Nephropathy Market Size 2014-2019 (Million US$)
Table Central & South America Key Players Diabetic Nephropathy Revenue (2018-2019) (Million US$)
Table Central & South America Key Players Diabetic Nephropathy Market Share (2018-2019)
Table Central & South America Diabetic Nephropathy Market Size by Type (2014-2019) (Million US$)
Table Central & South America Diabetic Nephropathy Market Share by Type (2014-2019)
Table Central & South America Diabetic Nephropathy Market Size by Application (2014-2019) (Million US$)
Table Central & South America Diabetic Nephropathy Market Share by Application (2014-2019)
Table Novartis Company Details
Table Novartis Revenue in Diabetic Nephropathy Business (2014-2019) (Million US$)
Figure Novartis Revenue Growth Rate in Diabetic Nephropathy Business (2014-2019)
Table Novartis Recent Development
Table Merck Company Details
Table Merck Revenue in Diabetic Nephropathy Business (2014-2019)(Million US$)
Figure Merck Revenue Growth Rate in Diabetic Nephropathy Business (2014-2019)
Table Merck Recent Development
Table Pfizer Company Details
Table Pfizer Revenue in Diabetic Nephropathy Business (2014-2019)(Million US$)
Figure Pfizer Revenue Growth Rate in Diabetic Nephropathy Business (2014-2019)
Table Pfizer Recent Development
Table Abbott Laboratories Company Details
Table Abbott Laboratories Revenue in Diabetic Nephropathy Business (2014-2019)(Million US$)
Figure Abbott Laboratories Revenue Growth Rate in Diabetic Nephropathy Business (2014-2019)
Table Abbott Laboratories Recent Development
Table Sanofi Company Details
Table Sanofi Revenue in Diabetic Nephropathy Business (2014-2019)(Million US$)
Figure Sanofi Revenue Growth Rate in Diabetic Nephropathy Business (2014-2019)
Table Sanofi Recent Development
Table Eli Lilly Company Details
Table Eli Lilly Revenue in Diabetic Nephropathy Business (2014-2019)(Million US$)
Figure Eli Lilly Revenue Growth Rate in Diabetic Nephropathy Business (2014-2019)
Table Eli Lilly Recent Development
Table AbbVie Company Details
Table AbbVie Revenue in Diabetic Nephropathy Business (2014-2019)(Million US$)
Figure AbbVie Revenue Growth Rate in Diabetic Nephropathy Business (2014-2019)
Table AbbVie Recent Development
Table Reata Pharmaceuticals Company Details
Table Reata Pharmaceuticals Revenue in Diabetic Nephropathy Business (2014-2019)(Million US$)
Figure Reata Pharmaceuticals Revenue Growth Rate in Diabetic Nephropathy Business (2014-2019)
Table Reata Pharmaceuticals Recent Development
Table Bayer Company Details
Table Bayer Revenue in Diabetic Nephropathy Business (2014-2019)(Million US$)
Figure Bayer Revenue Growth Rate in Diabetic Nephropathy Business (2014-2019)
Table Bayer Recent Development
Table Mitsubishi Tanabe Pharma Company Details
Table Mitsubishi Tanabe Pharma Revenue in Diabetic Nephropathy Business (2014-2019)(Million US$)
Figure Mitsubishi Tanabe Pharma Revenue Growth Rate in Diabetic Nephropathy Business (2014-2019)
Table Mitsubishi Tanabe Pharma Recent Development
Table Global Diabetic Nephropathy Market Size by Regions (Million US$) 2019-2025
Figure Global Diabetic Nephropathy Market Size Share by Regions (2019-2025)
Figure Global Diabetic Nephropathy Market Size Share by Regions in 2025
Figure United States Diabetic Nephropathy Market Size Forecast (2019-2025)(Million USD)
Figure Europe Diabetic Nephropathy Market Size Forecast (2019-2025)(Million USD)
Figure China Diabetic Nephropathy Market Size Forecast (2019-2025)(Million USD)
Figure Japan Diabetic Nephropathy Market Size Forecast (2019-2025)(Million USD)
Figure Southeast Asia Diabetic Nephropathy Market Size Forecast (2019-2025)(Million USD)
Figure India Diabetic Nephropathy Market Size Forecast (2019-2025)(Million USD)
Figure Central & South America Diabetic Nephropathy Market Size Forecast (2019-2025)(Million USD)
Table Global Diabetic Nephropathy Market Size by Product (2019-2025) (Million US$)
Figure Global Diabetic Nephropathy Market Size by Product (2019-2025)
Figure Global Diabetic Nephropathy Market Size by Product in 2025
Table Global Diabetic Nephropathy Market Size by Application (2019-2025) (Million US$)
Figure Global Diabetic Nephropathy Market Size by Application (2019-2025)
Figure Global Diabetic Nephropathy Market Size by Application in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
TNF阻害剤の世界市場：市場規模・現状・予測 TNF (tumor necrosis factor) inhibitors are anti-inflammatory drugs. TNF inhibitors help to block the TNF alpha that occurs naturally in the body and causes inflammation. TNF drugs are used to reduce inflammation and stop disease progression by targeting the tumor necrosis factor, which is an inflamm…- TNF阻害剤の世界市場：市場規模・現状・予測 TNF (tumor necrosis factor) inhibitors are anti-inflammatory drugs. TNF inhibitors help to block the TNF alpha that occurs naturally in the body and causes inflammation. TNF drugs are used to reduce inflammation and stop disease progression by targeting the tumor necrosis factor, which is an inflamm…
- IDO阻害剤の世界市場：インサイト・予測 The IDO (indoleamine 2,3-dioxygenase 1, IDO1, IDO-1, INDO, indoleamine-pyrrole 2,3-dioxygenase) inhibitors pipeline analysis report includes ongoing clinical and non-clinical trends in the global IDO inhibitors market. Most of the pipeline therapeutics are in early stage of development, the market i…
- 免疫チェックポイント阻害剤の世界市場：市場規模・現状・予測 Check point inhibitors are molecules that use the cosmic potential of the immune response system of the body, and its limitless influences to attack the cancer cells present inside the body, as well as avoids relapse of cancer cells. In case any relapse occurs in the body, it can easily be recognize…
- mTOR阻害剤の世界市場：インサイト・予測 mTOR inhibitors are a class of drugs that inhibit the mechanistic target of rapamycin (mTOR).Mammalian target of rapamycin (mTOR) inhibitors block the activity of the mammalian target of rapamycin. Mammalian target of rapamycin is a protein kinase, which regulates growth factors that stimulate cell …